bluuebunny/crossref_metadata_2025_split huggingface dataset:
Impact of severe SARS-CoV-2 infection on nutritional status and subjective functional loss in a prospective cohort of COVID-19 survivors
Authors: Quilliot Didier , Gérard Marine , Bonsack Olivier , Malgras Aurélie , Vaillant Marie-France , Di Patrizio Paolo , Jaussaud Roland , Ziegler Olivier , Nguyen-Thi Phi-Linh 
Published: July 2021

The nutritional sequelae of COVID-19 have not been explored in a large cohort study.ObjectivesTo identify factors associated with the change in nutritional status between discharge and 30 days post-discharge (D30). Secondary objectives were to determine the prevalence of subjective functional loss and severe disability at D30 and their associated factors.MethodsCollected data included symptoms, nutritional status, self-evaluation of food intake, Performance Status (PS) Scale, Asthenia Scale, self-evaluation of strength (SES) for arms and legs at discharge and at D30. An SES <7 was used to determine subjective functional loss. A composite criteria for severe disability was elaborated combining malnutrition, subjective functional loss and PS >2. Patients were classified into three groups according to change in nutritional status between discharge and D30 (persistent malnutrition, correction of malnutrition and the absence of malnutrition).ResultsOf 549 consecutive patients hospitalised for COVID-19 between 1 March and 29 April 2020, 130 died including 17 after discharge (23.7%). At D30, 312 patients were at home, 288 (92.3%) of whom were interviewed. Of the latter, 33.3% were malnourished at discharge and still malnourished at D30, while 23.2% were malnourished at discharge but no longer malnourished at D30. The highest predictive factors of persistent malnutrition were intensive care unit (ICU) stay (OR=3.42, 95% CI: 2.04 to 5.75), subjective functional loss at discharge (OR=3.26, 95% CI: 1.75 to 6.08) and male sex (OR=2.39, 95% CI: 1.44 to 3.97). Subjective functional loss at discharge (76.8%) was the main predictive factor of subjective functional loss at D30 (26.3%) (OR=32.6, 95% CI: 4.36 to 244.0). Lastly, 8.3% had a severe disability, with a higher risk in patients requiring an ICU stay (OR=3.39, 95% CI: 1.43 to 8.06).ConclusionPatients who survived a severe form of COVID-19 had a high risk of persistent malnutrition, functional loss and severe disability at D30. We believe that nutritional support and rehabilitation should be strengthened, particularly for male patients who were admitted in ICU and had subjective functional loss at discharge.Trial registration numberNCT04451694.
Flash glucose monitoring with the FreeStyle Libre 2 compared with self-monitoring of blood glucose in suboptimally controlled type 1 diabetes: the FLASH-UK randomised controlled trial protocol
Authors: Wilmot Emma G , Evans Mark , Barnard-Kelly Katharine , Burns M , Cranston Iain , Elliott Rachel Ann , Gkountouras G , Kanumilli N , Krishan A , Kotonya C , Lumley S , Narendran P , Neupane Sankalpa , Rayman Gerry , Sutton Christopher , Taxiarchi V P , Thabit H , Leelarathna L 
Published: July 2021

IntroductionOptimising glycaemic control in type 1 diabetes (T1D) remains challenging. Flash glucose monitoring with FreeStyle Libre 2 (FSL2) is a novel alternative to the current standard of care self-monitoring of blood glucose (SMBG). No randomised controlled trials to date have explored the potential benefits of FSL2 in T1D. We aim to assess the impact of FSL2 in people with suboptimal glycaemic control T1D in comparison with SMBG.MethodsThis open-label, multicentre, randomised (via stochastic minimisation), parallel design study conducted at eight UK secondary and primary care centres will aim to recruit 180 people age ≥16 years with T1D for >1 year and glycated haemoglobin (HbA1c) 7.5%–11%. Eligible participants will be randomised to 24 weeks of FSL2 (intervention) or SMBG (control) periods, after 2-week of blinded sensor wear. Participants will be assessed virtually or in-person owing to the COVID-19 pandemic. HbA1c will be measured at baseline, 12 and 24 weeks (primary outcome). Participants will be contacted at 4 and 12 weeks for glucose optimisation. Control participants will wear a blinded sensor during the last 2 weeks. Psychosocial outcomes will be measured at baseline and 24 weeks. Secondary outcomes include sensor-based metrics, insulin doses, adverse events and self-report psychosocial measures. Utility, acceptability, expectations and experience of using FSL2 will be explored. Data on health service resource utilisation will be collected.AnalysisEfficacy analyses will follow intention-to-treat principle. Outcomes will be analysed using analysis of covariance, adjusted for the baseline value of the corresponding outcome, minimisation factors and other known prognostic factors. Both within-trial and life-time economic evaluations, informed by modelling from the perspective of the National Health Service setting, will be performed.EthicsThe study was approved by Greater Manchester West Research Ethics Committee (reference 19/NW/0081). Informed consent will be sought from all participants.Trial registration numberNCT03815006.Protocol version4.0 dated 29 June 2020.
Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis
Authors: Imberti Jacopo F , Ding Wern Yew , Kotalczyk Agnieszka , Zhang Juqian , Boriani Giuseppe , Lip Gregory , Andrade Jason , Gupta Dhiraj 
Published: July 2021

ObjectiveTo assess the efficacy and safety of catheter ablation (CA) compared with antiarrhythmic drugs (AADs) as first-line treatment for symptomatic paroxysmal atrial fibrillation (AF).MethodsSystematic review and meta-analysis of randomised controlled trials identified using MEDLINE, Cochrane Library and Embase published between 01/01/2000 and 19/03/2021. The primary efficacy endpoint was the first documented recurrence of atrial arrhythmias following the blanking period. The primary safety endpoint was a composite of all serious adverse events (SAEs).ResultsFrom 441 records, 6 studies met the inclusion criteria. 609 patients received CA, while 603 received AAD therapy. 212/609 patients in the CA group had a recurrence of atrial arrhythmias as compared with 318/603 in the AADs group resulting in a 36% relative risk reduction (risk ratio: 0.64, 95% CI 0.51 to 0.80, p<0.01). The risk of all SAEs was not statistically different between CA and AAD (0.87, 0.58 to 1.30, p=0.49); 107/609 SAE in the CA group vs 126/603 in the AAD group. Both recurrence of symptomatic atrial arrhythmias (109/505 vs 186/504) and healthcare utilisation (126/397 vs 185/394) were significantly lower in the CA group (0.53, 0.35 to 0.79 and 0.65, 0.48 to 0.89, respectively). There was a 79% reduction in the crossover rate during follow-up among patients randomised to CA compared with AAD (0.21, 0.13 to 0.32, p<0.01).ConclusionsFirst-line treatment with CA is superior to AAD therapy in patients with symptomatic paroxysmal AF, as it significantly reduces the recurrence of any atrial arrhythmias and symptomatic atrial arrhythmias, and healthcare resource utilisation with comparable safety profile.
Lesional psychiatric neurosurgery: meta-analysis of clinical outcomes using a transdiagnostic approach
Authors: Davidson Benjamin , Eapen-John David , Mithani Karim , Rabin Jennifer S , Meng Ying , Cao Xingshan , Pople Christopher B , Giacobbe Peter , Hamani Clement , Lipsman Nir 
Published: July 2021

BackgroundFour ablative neurosurgical procedures are used in the treatment of refractory psychiatric illness. The long-term effects of these procedures on psychiatric symptoms across disorders has never been synthesised and meta-analysed.MethodsA preregistered systematic review was performed on studies reporting clinical results following ablative psychiatric neurosurgery. Four possible outcome measures were extracted for each study: depression, obsessive–compulsive symptoms, anxiety and clinical global impression. Effect sizes were calculated using Hedge’s g. Equipercentile linking was used to convert symptom scores to a common metric. The main outcome measures were the magnitude of improvement in depression, obsessive compulsive symptoms, anxiety and clinical global impression. The secondary outcome was a subgroup analysis comparing the magnitude of symptom changes between the four procedures.ResultsOf 943 articles, 43 studies reporting data from 1414 unique patients, were included for pooled effects estimates with a random-effects meta-analysis. Results showed that there was a large effect size for improvements in depression (g=1.27; p<0.0001), obsessive–compulsive symptoms (g=2.25; p<0.0001) and anxiety (g=1.76; p<0.0001). The pooled clinical global impression improvement score was 2.36 (p<0.0001). On subgroup analysis, there was only a significant degree of heterogeneity in effect sizes between procedure types for anxiety symptoms, with capsulotomy resulting in a greater reduction in anxiety than cingulotomy.ConclusionsContemporary ablative neurosurgical procedures were significantly associated with improvements in depression, obsessive–compulsive symptoms, anxiety and clinical global impression.PROSPERO registration numberCRD42020164784.
Family experiences with non-therapeutic research on dying patients in the intensive care unit
Authors: van Beinum Amanda , Murphy Nick , Weijer Charles , Gruben Vanessa , Sarti Aimee , Hornby Laura , Dhanani Sonny , Chandler Jennifer 
Published: July 2021

Experiences of substitute decision-makers with requests for consent to non-therapeutic research participation during the dying process, including to what degree such requests are perceived as burdensome, have not been well described. In this study, we explored the lived experiences of family members who consented to non-therapeutic research participation on behalf of an imminently dying patient.We interviewed 33 family members involved in surrogate research consent decisions for dying patients in intensive care. Non-therapeutic research involved continuous physiological monitoring of dying patients prior to and for 30 min following cessation of circulation. At some study centres participation involved installation of bedside computers. At one centre electroencephalogram monitoring was used with a subset of participants. Aside from additional monitoring, the research protocol did not involve deviations from usual end-of-life care.Thematic analysis of interviews suggests most family members did not perceive this minimal-risk, non-therapeutic study to affect their time with patients during the dying process, nor did they perceive research consent as an additional burden. In our analysis, consenting for participation in perimortem research offered families of the dying an opportunity to affirm the intrinsic value of patients’ lives and contributions. This opportunity may be particularly important for families of patients who consented to organ donation but did not proceed to organ retrieval.Our work supports concerns that traditional models of informed consent fail to account for possible benefits and harms of perimortem research to surviving families. Further research into consent models which integrate patient and family perspectives is needed.
Generalizing the coupling between geometry and matter: $$f\left( R,L_m,T\right) $$ gravity
Authors: Haghani Zahra , Harko Tiberiu 
Published: July 2021

AbstractWe generalize and unify the $$f\left( R,T\right) $$

f

R
,
T

and $$f\left( R,L_m\right) $$

f

R
,

L
m

type gravity models by assuming that the gravitational Lagrangian is given by an arbitrary function of the Ricci scalar R, of the trace of the energy–momentum tensor T, and of the matter Lagrangian $$L_m$$

L
m

, so that $$ L_{grav}=f\left( R,L_m,T\right) $$

L

grav

=
f

R
,

L
m

,
T

. We obtain the gravitational field equations in the metric formalism, the equations of motion for test particles, and the energy and momentum balance equations, which follow from the covariant divergence of the energy–momentum tensor. Generally, the motion is non-geodesic, and takes place in the presence of an extra force orthogonal to the four-velocity. The Newtonian limit of the equations of motion is also investigated, and the expression of the extra acceleration is obtained for small velocities and weak gravitational fields. The generalized Poisson equation is also obtained in the Newtonian limit, and the Dolgov–Kawasaki instability is also investigated. The cosmological implications of the theory are investigated for a homogeneous, isotropic and flat Universe for two particular choices of the Lagrangian density $$f\left( R,L_m,T\right) $$

f

R
,

L
m

,
T

of the gravitational field, with a multiplicative and additive algebraic structure in the matter couplings, respectively, and for two choices of the matter Lagrangian, by using both analytical and numerical methods.
Passage of heavy quarks through the fluctuating hot QCD medium
Authors: Jamal Mohammad Yousuf , Mohanty Bedangadas 
Published: July 2021

AbstractThe change in the energy of the moving heavy (charm and bottom) quarks due to field fluctuations present in the hot QCD medium has been studied. A finite quark chemical potential has been considered while modeling the hot QCD medium counting the fact that the upcoming experimental facilities such as Facility for Anti-proton and Ion Research (FAIR) and Nuclotron-based Ion Collider fAcility (NICA) are expected to operate at finite baryon density and moderate temperature. The effective kinetic theory approach has been adopted where the collisions have been incorporated using the well-defined collisional kernel, known as Bhatnagar–Gross–Krook (BGK). To incorporate the non-ideal equations of state (EoSs) effects/medium interaction effects, an extended effective fugacity model has been adopted. The momentum dependence of the energy change due to fluctuation for the charm and bottom quark has been investigated at different values of collision frequency and chemical potential. The results are exciting as the heavy quarks are found to gain energy due to fluctuations while moving through the produced medium at finite chemical potential and collision frequency.
Algebraic Approach to Promise Constraint Satisfaction
Authors: Barto Libor , Bulín Jakub , Krokhin Andrei , Opršal Jakub 
Published: July 2021

The complexity and approximability of the constraint satisfaction problem (CSP) has been actively studied over the past 20 years. A new version of the CSP, the promise CSP (PCSP), has recently been proposed, motivated by open questions about the approximability of variants of satisfiability and graph colouring. The PCSP significantly extends the standard decision CSP. The complexity of CSPs with a fixed constraint language on a finite domain has recently been fully classified, greatly guided by the algebraic approach, which uses polymorphisms—high-dimensional symmetries of solution spaces—to analyse the complexity of problems. The corresponding classification for PCSPs is wide open and includes some long-standing open questions, such as the complexity of approximate graph colouring, as special cases.

The basic algebraic approach to PCSP was initiated by Brakensiek and Guruswami, and in this article, we significantly extend it and lift it from concrete properties of polymorphisms to their abstract properties. We introduce a new class of problems that can be viewed as algebraic versions of the (Gap) Label Cover problem and show that every PCSP with a fixed constraint language is equivalent to a problem of this form. This allows us to identify a “measure of symmetry” that is well suited for comparing and relating the complexity of different PCSPs via the algebraic approach. We demonstrate how our theory can be applied by giving both general and specific hardness/tractability results. Among other things, we improve the state-of-the-art in approximate graph colouring by showing that, for any
k
≥ 3, it is NP-hard to find a (2
k
-1)-colouring of a given
k
-colourable graph.
Socioeconomic Burden of Rising Methamphetamine-Associated Heart Failure Hospitalizations in California From 2008 to 2018
Authors: Zhao Susan X. , Deluna Andres , Kelsey Kate , Wang Clifford , Swaminathan Aravind , Staniec Allison , Crawford Michael H. 
Published: July 2021

Background:
Methamphetamine-associated cardiomyopathy/heart failure (MethHF) is an increasingly recognized disease entity in the context of a rising methamphetamine (meth) epidemic that most severely impacts the western United States. Using heart failure (HF) hospitalization data from the Office of Statewide Health Planning and Development, this study aimed to assess trend and disease burden of MethHF in California.

Methods:

Adult patients (≥18 years old) with HF as primary hospitalization diagnosis between 2008 and 2018 were included in this study. The association with Meth (MethHF) and those without (non-MethHF) were determined by meth-related
International Classification of Diseases
-based secondary diagnoses. Statistical significance of trends in age-adjusted rates of hospitalization per 100 000 adults were evaluated using nonparametric analysis.

Results:

Between 2008 and 2018, 1 033 076 HF hospitalizations were identified: 42 565 were MethHF (4.12%) and 990 511 (95.88%) were non-MethHF. Age-adjusted MethHF hospitalizations per 100 000 increased by 585% from 4.1 in 2008 to 28.1 in 2018, while non-MethHF hospitalizations decreased by 6.0% from 342.3 in 2008 to 321.6 in 2018. The rate of MethHF hospitalization increase more than doubled that of a negative control group with urinary tract infection and meth-related secondary diagnoses (7.82-fold versus 3.48-fold,
P
<0.001). Annual inflation–adjusted hospitalization charges because of MethHF increased by 840% from $41.5 million in 2008 to $390.2 million in 2018, as compared with an 82% increase for all HF hospitalization from $3.503 billion to $6.376 billion. Patients with MethHF were significantly younger (49.64±10.06 versus 72.20±14.97 years old,
P
<0.001), predominantly male (79.1% versus 52.4%,
P
<0.001), with lower Charlson Comorbidity Index, yet they had longer length of stay, more hospitalizations per patient, and more procedures performed during their stays.

Conclusions:
MethHF hospitalizations increased sharply during the study period and contributed significantly to the HF hospitalization burden in California. This emerging HF phenotype, which engenders considerable financial and societal costs, calls for an urgent and concerted public health response to contain its spread.
Interplay Between Myocardial Bridging and Coronary Spasm in Patients With Myocardial Ischemia and Non‐Obstructive Coronary Arteries: Pathogenic and Prognostic Implications
Authors: Montone Rocco A. , Gurgoglione Filippo Luca , Del Buono Marco Giuseppe , Rinaldi Riccardo , Meucci Maria Chiara , Iannaccone Giulia , La Vecchia Giulia , Camilli Massimiliano , D’Amario Domenico , Leone Antonio Maria , Vergallo Rocco , Aurigemma Cristina , Buffon Antonino , Romagnoli Enrico , Burzotta Francesco , Trani Carlo , Crea Filippo , Niccoli Giampaolo 
Published: July 2021

Background
Myocardial bridging (MB) may represent a cause of myocardial ischemia in patients with non‐obstructive coronary artery disease (NOCAD). Herein, we assessed the interplay between MB and coronary vasomotor disorders, also evaluating their prognostic relevance in patients with myocardial infarction and non‐obstructive coronary arteries (MINOCA) or stable NOCAD.

Methods and Results

We prospectively enrolled patients with NOCAD undergoing intracoronary acetylcholine provocative test. The incidence of major adverse cardiac events, defined as the composite of cardiac death, non‐fatal myocardial infarction, and rehospitalization for unstable angina, was assessed at follow‐up. We also assessed angina status using Seattle Angina Questionnaires summary score. We enrolled 310 patients (mean age, 60.6±11.9; 136 [43.9%] men; 169 [54.5%] stable NOCAD and 141 [45.5%] MINOCA). MB was found in 53 (17.1%) patients. MB and a positive acetylcholine test coexisted more frequently in patients with MINOCA versus stable NOCAD. MB was an independent predictor of positive acetylcholine test and MINOCA. At follow‐up (median, 22 months; interquartile range, 13–32), patients with MB had a higher rate of major adverse cardiac events, mainly driven by a higher rate of hospitalization attributable to angina, and a lower Seattle Angina Questionnaires summary score (all
P
<0.001) compared with patients without MB. In particular, the group of patients with MB and a positive acetylcholine test had the worst prognosis.

Conclusions
Among patients with NOCAD, coronary spasm associated with MB may predict a worse clinical presentation with MINOCA and a higher rate of hospitalization attributable to angina at long‐term follow‐up with a low rate of hard events.
Endonuclease V
Regulates Atherosclerosis Through C‐C Motif Chemokine Ligand 2‐Mediated Monocyte Infiltration
Authors: Kong Xiang Yi , Huse Camilla , Yang Kuan , Øgaard Jonas , Berges Natalia , Vik Erik Sebastian , Nawaz Meh Sameen , Quiles‐Jiménez Ana , Abbas Azhar , Gregersen Ida , Holm Sverre , Bjerkli Vigdis , Rashidi Azita , Fladeby Cathrine , Suganthan Rajikala , Sagen Ellen Lund , Skjelland Mona , Lång Anna , Bøe Stig Ove , Bjørås Magnar , Aukrust Pål , Alseth Ingrun , Halvorsen Bente , Dahl Tuva Børresdatter 
Published: July 2021

Background
In cardiovascular diseases, atherosclerotic disorder are the most frequent and important with respect to morbidity and mortality. Inflammation mediated by immune cells is central in all parts of the atherosclerotic progress, and further understanding of the underlying mechanisms is needed. Growing evidence suggests that deamination of adenosine‐to‐inosine in RNA is crucial for a correct immune response; nevertheless, the role of adenosine‐to‐inosine RNA editing in atherogenesis has barely been studied. Several proteins have affinity for inosines in RNA, one being ENDOV (endonuclease V), which binds and cleaves RNA at inosines. Data on ENDOV in atherosclerosis are lacking.

Methods and Results

Quantitative polymerase chain reaction on ENDOV mRNA showed an increased level in human carotid atherosclerotic plaques compared with control veins. Inosine‐ribonuclease activity as measured by an enzyme activity assay is detected in immune cells relevant for the atherosclerotic process. Abolishing
EndoV
in atherogenic apolipoprotein E‐deficient (

ApoE
−/−

) mice reduces the atherosclerotic plaque burden, both in size and lipid content. In addition, in a brain stroke model, mice without ENDOV suffer less damage than control mice. Finally, lack of
EndoV
reduces the recruitment of monocytes to atherosclerotic lesions in atherogenic

ApoE
−/−

mice.

Conclusions

ENDOV
is upregulated in human atherosclerotic lesions, and data from mice suggest that ENDOV promotes atherogenesis by enhancing the monocyte recruitment into the atherosclerotic lesion, potentially by increasing the effect of CCL2 activation on these cells.